Margaret Block, MD
Hematology & Oncology · Omaha, NENPI 1184604118
Payments from drug & device makers
Across 1,372 payments — averaging $6057.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3.5M
- Seagen Inc.$1.5M
- Novartis$961K
- Merck$761K
- Genentech, Inc.$538K
- Eli Lilly$448K
- plus $586K from 22 others
Across 2 payments — averaging $206,600 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$413K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 244 | $3,469,272 |
| Seagen Inc. | 282 | $1,546,926 |
| Novartis | 16 | $960,928 |
| Merck | 133 | $761,242 |
| Genentech, Inc. | 590 | $538,074 |
| Eli Lilly | 20 | $447,896 |
| AstraZeneca | 16 | $218,828 |
| Amgen | 4 | $188,203 |
| F. Hoffmann-la Roche AG | 5 | $63,042 |
| Janssen Research & Development, LLC | 13 | $60,299 |
| Jazz Pharmaceuticals Inc. | 2 | $29,025 |
| Incyte Corporation | 19 | $24,334 |
| Gilead | 2 | $1,622 |
| Aimmune Therapeutics, Inc. | 2 | $189 |
| AbbVie | 5 | $117 |
| Astrazeneca UK Limited | 1 | $72 |
| E.r. Squibb & Sons, L.L.C. | 4 | $56 |
| Daiichi Sankyo Inc. | 2 | $53 |
| AVEO Pharmaceuticals, Inc. | 2 | $40 |
| Recordati_rare_diseases_inc. | 1 | $39 |
| Array Biopharma Inc | 2 | $21 |
| Johnson & Johnson | 1 | $18 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $16 |
| CTI Biopharma Corp. | 1 | $16 |
| Sirtex Medical Inc | 1 | $15 |
| Servier Pharmaceuticals LLC | 1 | $15 |
| Bristol Myers Squibb | 1 | $14 |
| Epizyme, Inc. | 1 | $12 |
How this compares
$8,310,383 in reported general payments places this provider in the 95th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Omaha
- Luke NordquistOmaha$29.3M
- Ralph HaukeOmaha$12.1M
- Stefano TarantoloOmaha$3.7M
- Julie VoseOmaha$3.5M
- Robert BociekOmaha$3M
- Vijaya BhattOmaha$2.2M
- Mojtaba AkhtariOmaha$1.9M
- Mary WellsOmaha$1.6M
- Robert LangdonOmaha$1.2M
- Yungpo SuOmaha$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.